the aid library

LIST OPTIONS

Filter

1699

Sort by:

Direction:

Download (69004)

View PDF (1430)

Petunjuk Praktis Terapi Insulin pada Pasien Diabetes Melitus

Indonesian Society of Internal Medicine (2006) C1

Practical Guidelines of Insulin Therapy in Diabetes Mellitus Patients

Download (1146)

View PDF (1966)

Konsensus Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia

Indonesian Society of Internal Medicine (2006) C1

Guidelines and Consensus for the Diagnosis, Management and Prevention of Type 2 Diabetes Mellitus in Indonesia

Download (425)

View PDF (560)

Diabetes Mellitus: Diagnosis and Management Guidelines

Sv Madhu, S. Srivastava (2015) CC

JIMSA Jan.-March 2015 Vol. 28 no.1 p.47-50e

Download (533)

View PDF (1153)

ICMR Guidelines for Management of Type 2 Diabetes 2018

ICMR Indian Council of Medical Research (2018) C1

Download (85)

View PDF (737)

Methicillin-ResistantStaphylococcus aureus(MRSA):Prevalence and Antimicrobial Sensitivity Pattern among Patients—A Multicenter Study in Asmara, Eritrea

Yohaness Garoy E., Y. Berhane Gebreab, O. Okoth Achila et al. Hindawi (2018) C2

Methicillin-resistant Staphylococcus aureus(MRSA) strainsor multidrug-resistant S.aureus, initially described in 1960s,emerged in the last decade as a cause of nosocomial infections responsible for rapidly progressive, potential fatal diseases including life-threatening pneumonia, necrotizing fascii... more

Download (138)

View PDF (130)

Was bedeutet eine Virusinfektion für den Stoffwechsel, und wie kann die Diabetestherapie daraufhin angepasst werden?

Deutsche Diabetes Hilfe (2021) CC

Download (105)

View PDF (138)

Typ-1-Diabetes und Covid-19 – Therapieanpassung in einer Extremsituation

Deutsche Diabetes Hilfe (2021) CC

Hilfestellung zur Diabetestherapie in häuslicher Quarantäne während einer Pandemie

Download (117)

View PDF (153)

Diabetes und Therapie. Russian Version. Лечение диабета 2-го типа

Ärztliches Zentrum für Qualität in der Medizin (ÄZQ) (2022) C2

Диабет 2-го типа или «сахар» широко распространен среди взрослых. Характерный признак болезни – постоянно повышенный уровень сахара в крови. Без правильного лечен... more

Download (142)

View PDF (123)

Guía Clínica – Diabetes Mellitus tipo 1

Ministerio de Salud Chile (2013) C2

Guía Clínica – Diabetes Mellitus tipo 1

Download (244)

View PDF (328)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (20)

View PDF (15)

Clinical Profile and Management of Patient Patients with Ischemic Heart Disease and/or Peripheral Artery Disease in Clinical Practice: The APALUSA Study

Barrios, V.; Escobar, C.; Suarez C. et al. Journal of Clinical Medicine (2022) CC

This study was aimed to ascertain the clinical profile and management of patients with ischemic heart disease (IHD) and/or peripheral artery disease (PAD). In this observational and cross-sectional study developed in 80 hospitals throughout Spain, consecutive adults with stable IHD and/or PAD were i... more

Download (35)

View PDF (23)

Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes

Park, J.J. Diabetes & Metabolism Journal (2021) CC

The cardiovascular disease continuum begins with risk factors such as diabetes mellitus (DM), progresses to vasculopathy and myocardial dysfunction, and finally ends with cardiovascular death. Diabetes is associated with a 2- to 4-fold increased risk for heart failure (HF). Moreover, HF patients wit... more

Download (9)

View PDF (9)

The many faces of diabetes. Is there a need for re-classification? A narrative review

Sakran, N.; Graham, Yiitka.; Pintar, T.; et al. BMC Endocrine Disorders Volume 22 Article Number 9 (2022) CC

The alarming rise in the worldwide prevalence of obesity and associated type 2 diabetes mellitus (T2DM) have reached epidemic portions. Diabetes in its many forms and T2DM have different physiological backgrounds and are difficult to classify. Bariatric surgery (BS) is considered the most effective ... more

Download (23)

View PDF (20)

Population and Individual Approach to the Prevention and Management of Diabetes and Obesity

Pan American Health Organization PAHO (2011) C_WHO

The Resolution Population and Individual Approaches to the Prevention and Management of Diabetes and Obesity was approved by the 48th Directing Council of the Pan American Health Organization, September 29- October 3, 2008, in response to the epidemic of obesity and diabetes currently affecting the ... more

Download (21)

View PDF (22)

MEPs Mobilising for Diabetes Blueprint for Action on Diabetes in the European Union by 2030

MEPs Mobilising for Diabetes (2021) CC2

Since the discovery of insulin nearly 100 years ago, advances in diabetes treatments and therapies have transformed the lives of people with diabetes (PwD), notably reducing the daily burden of its management. Newer technologies, including those driven by artificial intelligence, have the potentia... more

Download (18)

View PDF (23)

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the Eur

Marx, N.; Federici, M.; Schütt, K. et al. European Heart Journal (2023) CC

Patients with diabetes are at increased risk of developing cardiovascular disease (CVD) with its manifestations of coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), and stroke, as well as aortic and peripheral artery diseases. In addition, diabetes is a major risk factor f... more

Download (19)

View PDF (26)

Population and Individual Approaches to the Prevention and Management of Diabetes and Obesity

Pan American Health Organization PAHO (2011) C_WHO

Obesity and diabetes are affecting the peoples of the Americas at high and increasing rates. National surveys demonstrate that obesity is increasing in prevalence among all age groups; 7% to 12% of children under 5 years old and one-fi fth of adolescents are obese, while rates of overweight and obe... more

Download (18)

View PDF (11)

Type 2 diabetes in adults: choosing medicines

National Institute for Health and Care Excellence (2022) CC2

Factors to take into account when choosing, reviewing and changing medicines. Rescue therapy: For symptomatic hyperglycaemia, consider insulin or a sulfonylurea and review when blood glucose control has been achieved. Diet and lifestyle advice: At each point reinforce advice about diet and life... more

Download (17)

View PDF (18)

ICMR Guidlines for management of type 2 Diabetes

Indian Council of Medical Research (2018) CC2

In recent decades, India has witnessed a rapidly exploding epidemic of diabetes. Indeed, India today has the second largest number of people with diabetes in the world. The International Diabetes Federation (IDF) estimates that there are 72.9 million people with diabetes in India in 2017, which is... more

Download (9)

View PDF (12)

Diabetes in children and young people

National Institute for Health and Care Excellence (NICE) National Institute for Health and Care Excellence (NICE) (2022) CC2

The document "Diabetes in Children and Young People" by NICE (National Institute for Health and Care Excellence) provides quality standards for the diagnosis, management, and support of diabetes in children and adolescents.